SCHEMBL7920183

SCHEMBL7920183

CCOC(=O)c1cnc2ccc(Br)nc2c1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.46
DYRK1A Q13627 5/20 0.45
ALDH1A1 P00352 5/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
MAPT P10636 3/20 0.45
LMNA P02545 2/20 0.45
ATM Q13315 1/20 0.45
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
TP53 P04637 2/20 0.44
GAA P10253 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
HSD17B10 Q99714 1/20 0.43
KMT2A Q03164 2/20 0.42
KDM4E B2RXH2 2/20 0.42
MEN1 O00255 1/20 0.42
CYP1A2 P05177 1/20 0.42
POLB P06746 1/20 0.42
CYP2C9 P11712 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29810196 1.00 MAPK1 (0.46) MAPK1DYRK1AALDH1A1SMN1; SMN2MAPT
SCHEMBL20421412 0.89 KMT2A (0.44) MAPK1DYRK1AALDH1A1SMN1; SMN2MAPT
SCHEMBL3373163 0.86 DYRK1A (0.47) MAPK1DYRK1AALDH1A1SMN1; SMN2MAPT
SCHEMBL3107549 0.86 DYRK1A (0.45) MAPK1DYRK1AALDH1A1SMN1; SMN2MAPT
SCHEMBL8327180 0.84 DYRK1A (0.45) MAPK1DYRK1AALDH1A1SMN1; SMN2MAPT
SCHEMBL8326859 0.84 DYRK1A (0.45) MAPK1DYRK1AALDH1A1SMN1; SMN2MAPT
SCHEMBL3786466 0.84 TSHR (0.46) MAPK1DYRK1AALDH1A1SMN1; SMN2MAPT
SCHEMBL29810205 0.84 DYRK1A (0.50) MAPK1DYRK1AALDH1A1SMN1; SMN2MAPT
SCHEMBL6286366 0.84 DYRK1A (0.50) MAPK1DYRK1AALDH1A1SMN1; SMN2MAPT
SCHEMBL29810202 0.84 DYRK1A (0.50) MAPK1DYRK1AALDH1A1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2719697-B1 PYRIDONAPHTHYRIDINE PI3K/MTOR DUAL INHIBITORS AND PREPARATION AND USE THEREOF XUANZHU PHARMA CO LTD (CN) 2018-08-01 EP disclosed
EP-2886540-B1 BICYCLIC SUBSTITUTED PYRIMIDINE COMPOUNDS XUANZHU PHARMA CO LTD (CN) 2017-07-26 EP disclosed
EP-2886540-B1 BICYCLIC SUBSTITUTED PYRIMIDINE COMPOUNDS XUANZHU PHARMA CO LTD (CN) 2017-07-26 EP disclosed
US-9475812-B2 Pyridonaphthyridine type dual PI3K and mTOR inhibitor and its preparation and use Xuanzhu Pharma Co., Ltd. (CN) 2016-10-25 US disclosed
EP-2356120-B1 IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER (US) 2016-10-12 EP disclosed
US-9359371-B2 Bicyclic substituted pyrimidine compounds Xuanzhu Pharma Co., Ltd. (CN) 2016-06-07 US disclosed
US-9359371-B2 Bicyclic substituted pyrimidine compounds Xuanzhu Pharma Co., Ltd. (CN) 2016-06-07 US disclosed
EP-2781520-B1 THREE-RING PI3K AND/OR MTOR INHIBITOR XUANZHU PHARMA CO LTD (CN) 2016-05-04 EP disclosed
US-9284315-B2 Three-ring PI3K and/or mTOR inhibitor ZUANZHU PHARMA CO., LTD. (CN) 2016-03-15 US disclosed
US-9284315-B2 Three-ring PI3K and/or mTOR inhibitor ZUANZHU PHARMA CO., LTD. (CN) 2016-03-15 US disclosed
US-20150166539-A1 THREE-RING PI3K AND/OR MTOR INHIBITOR Xuanzhu Pharma Co., Ltd. (CN) 2015-06-18 US disclosed
US-20150166539-A1 THREE-RING PI3K AND/OR MTOR INHIBITOR Xuanzhu Pharma Co., Ltd. (CN) 2015-06-18 US disclosed
EP-2781520-A1 THREE-RING PI3K AND/OR MTOR INHIBITOR Xuanzhu Pharma Co., Ltd. (CN) 2014-09-24 EP disclosed
US-8791131-B2 Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions PFIZER INC. (US) 2014-07-29 US disclosed
US-8791131-B2 Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions PFIZER INC. (US) 2014-07-29 US disclosed
EP-2719697-A1 PYRIDONAPHTHYRIDINE PI3K/MTOR DUAL INHIBITORS AND PREPARATION AND USE THEREOF Xuanzhu Pharma Co., Ltd. (CN) 2014-04-16 EP disclosed
WO-2013071698-A1 THREE-RING PI3K AND/OR MTOR INHIBITOR 山东轩竹医药科技有限公司 (CN) 2013-05-23 WO disclosed
US-20110190326-A1 IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC. 2011-08-04 US disclosed
US-20110190326-A1 IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC. 2011-08-04 US disclosed
WO-2010038165-A1 IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC. (US) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150166539-A1 THREE-RING PI3K AND/OR MTOR INHIBITOR MTOR, RICTOR, AKT3 MAPK1 74/4885DYRK1A 995/4885ALDH1A1 4602/4885
US-20110190326-A1 IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS PIK3CA, PIK3CD, PIK3R5 MAPK1 272/4885DYRK1A 296/4885ALDH1A1 3352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.